Physician profile
Luis A Ortiz
NPI 1114026242
$947.93
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $96.50 · 2021: $324 · 2022: $115 · 2023: $80.02 · 2024: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $183.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $435.53 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $119.93 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $60.00 | 2023 | |
| Novo Nordisk INC | $45.14 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $43.59 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $36.73 | 2020 | |
| Leadiant Biosciences, INC. | $33.66 | 2024 | Cystaran |
| Takeda Pharmaceuticals U.S.A., INC. | $26.64 | 2024 | Livtencity |
| Astellas Pharma US INC | $25.67 | 2024 | Cresemba |
| Eusa Pharma (US) LLC | $23.93 | 2022 | |
| Recordati_rare_diseases_inc. | $23.92 | 2022 | |
| Silvergate Pharmaceuticals, INC. | $23.78 | 2020 | |
| Glaxosmithkline, LLC. | $20.02 | 2023 | Benlysta |
| Abiomed | $17.47 | 2024 | Impella |
| Travere Therapeutics, INC. | $11.92 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.